Preview

Рецепт

Расширенный поиск

Осельтамивир: применение при гриппе

https://doi.org/10.34883/PI.2020.23.1.012

Полный текст:

Аннотация

В статье представлены обзорные данные эффективности и безопасности применения осельтамивира в клинической практике, полученные в рандомизированных клинических плацебо-контролируемых исследованиях среди пациентов невысокого риска с неосложненным лабораторно подтвержденным гриппом и в наблюдательных исследованиях госпитализированных пациентов, а также приведены результаты систематических обзоров и метаанализов исследований эффективности и безопасности применения осельтамивира. Показано преимущество назначения ингибитора нейраминидазы осельтамивира при гриппе, заключающееся в значительном снижении тяжести и продолжительности заболевания, а также вторичных осложнений у детей, пожилых пациентов и пациентов высокого риска. Подчеркнута возможность достижения большего клинического эффекта при раннем (в течение 6–12 часов от момента появления клинических симптомов) начале лечения осельтамивиром. Отмечена его эффективность в профилактике гриппа А и В, а также хорошая переносимость и безопасность.

Об авторе

О. Ф. Кардаш
Государственное предприятие «АКАДЕМФАРМ»
Беларусь

 Минск 



Список литературы

1. (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet, vol. 392, pp. 1789–858.

2. Thokagevistk K. (2018) Global Burden of Seasonal Influenza Disease: A Structured Literature Review. Value in health, vol. 21, Suppl. 1, pp. S149–S150.

3. (2019) Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Paget and the Global Seasonal Influenza-associated Mortality Collaborator Network and GLaMOR Collaborating Teams. Journal of health global, vol. 9, no. 2.

4. Federici C. (2018) Health care costs of influenza-related episodes in high income countries: A systematic review. PLoS ONE, vol. 13, Iss. 9, pp. e0202787.

5. (2020) Influenza vaccine effectiveness against influenza-related mortality in Australian hospitalized patients: a propensity score analysis/ Monica L Nation on behalf of the FluCAN Investigators. Clinical Infectious Diseases. Available at: https://doi.org/10.1093/cid/ciz1238.

6. Belongia E.A. (2016) Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. The Lancet Infectious diseases, vol. 16, Iss. 8, pp. 942–951.

7. (2018) Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Godoy Pere, The Working Group on Surveillance of Severe Influenza Hospitalized Cases in Catalonia. Euro Surveill, vol. 23, Iss. 43.

8. Treanor J.J. (2000) Efcacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA, vol. 283, Iss. 8, pp. 1016–24.

9. Nicholson K.G. (2000) Efcacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet, vol. 355, pp. 1845–50.

10. Whitley R.J. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J., vol. 20, pp. 127–33.

11. Jefferson T. (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev., pp. CD008965.

12. Dobson J. (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet, vol. 385, pp. 1729–37.

13. Malosh R.E. (2018) Efcacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis., vol. 66, pp. 1492–500.

14. Heinonen S. (2010) Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis., vol. 51, pp. 887–94.

15. Dobson J. (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet, vol. 385, pp. 1729–37.

16. Aoki F.Y., IMPACT Study Group (2003) Early administration of oral oseltamivir increases the benefts of influenza treatment. J Antimicrob Chemother, vol. 51, Iss. 1, pp. 123–9.

17. Muthuri S.G., PRIDE Consortium Investigators (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med., vol. 2, pp. 395–404.

18. Louie J.K. (2012) Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1) pdm09. Clin Infect Dis., vol. 55, pp. 1198–1204.

19. Venkatesan S. (2017) Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis., vol. 64, pp. 1328–34.

20. Cofn S.E. (2011) Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J., vol. 30, pp. 962–6.

21. Eriksson C.O. (2012) Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A. Pediatr Crit Care Med., vol. 13, pp. 625–31.

22. Lee N. (2015) Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J., vol. 45, pp. 1642–52.

23. Lam J. (2011) Severe cases of pandemic H1N1 pneumonia and respiratory failure requiring intensive care. J Intensive Care Med., vol. 2, Iss. 5, pp. 318–25.

24. (2010) Pandemic 2009 Influenza A(H1N1) Virus Illness Among Pregnant Women in the United States. A. M. Siston, the Pandemic H1N1 Influenza in Pregnancy Working Group. JAMA, vol. 303, Iss. 15, pp. 1517–1525.

25. Yates L. (2010) Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technology Assessment, vol. 14, no. 34, pp. 109–182.

26. (2011) Maternal and Infant Outcomes Among Severely Ill Pregnant and Postpartum Women with 2009 Pandemic Influenza A (H1N1) – United States, April 2009 – August 2010. MMWR – Morb Mortal Wkly Rep., vol. 60, pp. 1193–6.

27. Hayden F.G. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med., vol. 341, Iss. 18, pp. 1336–1343.

28. Hayden F.G. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA, vol. 282, pp. 1240–6.

29. Uyek T.M. (2018) Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clinical Infectious Diseases, vol. 20, pp. 1–47.


Рецензия

Для цитирования:


Кардаш О.Ф. Осельтамивир: применение при гриппе. Рецепт. 2020;24(1):116-120. https://doi.org/10.34883/PI.2020.23.1.012

For citation:


Kardash V. Oseltamivir: Use in Influenza. Recipe. 2020;24(1):116-120. (In Russ.) https://doi.org/10.34883/PI.2020.23.1.012

Просмотров: 22


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)